SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

CHSN: trading halted on Nasdaq — volatility pause (2:38 PM ET)

Nasdaq halted trading in CHSN (volatility pause) at 2:38 PM ET.

CHSN
SquawkNews Desk 4 updates Updated Nov 04, 2026, 08:06 PM UTC

Story updates

07:44:27 PM UTC
SquawkNews
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:44 PM
07:52:34 PM UTC
SquawkNews
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:52 PM
07:58:15 PM UTC
SquawkNews
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:58 PM
08:06:51 PM UTC
SquawkNews
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:06 PM

Related stories

Lilly Phase 3 Trial Reports Average 21.4% BMI Reduction With Zepbound The SURMOUNT-ADOLESCENTS trial showed Zepbound reduced BMI by an average of 21.4% in adolescents aged 12 to under 18 with obesity. M impact | EQUITY | Nov 14, 2026, 05:01 PM UTC Lilly Phase 2 Data Show Eloratzp Weight Loss of Up to 54.1 Pounds Phase 2 data showed average weight loss of up to 54.1 pounds (23.3%) at 48 weeks in adults with obesity and type 2 diabetes. M impact | EQUITY | Nov 14, 2026, 05:01 PM UTC Novo Nordisk CagriSema Reduced Waist Circumference by 17.2–17.5 cm Both CagriSema doses reduced waist circumference by 17.2–17.5 cm, versus 3.6 cm with placebo. M impact | EQUITY | Nov 14, 2026, 05:00 PM UTC Novo Nordisk CagriSema Shows Weight Loss in REDEFINE 9 Trial At 68 weeks, average weight loss was 20.7% with 1.7 mg/1.7 mg and 21.0% with 1.0 mg/1.0 mg, versus 2.0% with placebo. M impact | EQUITY | Nov 14, 2026, 05:00 PM UTC Novo Nordisk Says CagriSema Reduced Waist Circumference Up to 17.5 cm Both CagriSema doses reduced waist circumference by 17.2–17.5 cm, versus 3.6 cm with placebo. M impact | EQUITY | Nov 14, 2026, 05:00 PM UTC DUFFY: WE NEED L3HARRIS OR WHOEVER PROVIDED ROUTER TO DO A BETTER JOB L impact | EQUITY | Nov 14, 2026, 04:32 PM UTC